Reply to the letter to the editor 'Response to the effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors' by Ogale

Affiliations

¹ Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA. Electronic address: glopes.md@gmail.com.
² Faculdade de Medicina do ABC, Santo André; Americas Centro de Oncologia Integrado, São Paulo, Brazil.

Free article

Comment

G de Lima Lopes et al. Ann Oncol. 2019.

Free article

. 2019 Jan 1;30(1):149-150.

doi: 10.1093/annonc/mdy501.

¹ Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA. Electronic address: glopes.md@gmail.com.
² Faculdade de Medicina do ABC, Santo André; Americas Centro de Oncologia Integrado, São Paulo, Brazil.

No abstract available

Comment on

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.
Aguiar PN Jr, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, de Mello RA, Lopes GL Jr. Aguiar PN Jr, et al. Ann Oncol. 2017 Sep 1;28(9):2256-2263. doi: 10.1093/annonc/mdx305. Ann Oncol. 2017. PMID: 28633409
Response to 'The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors'.
Ogale S. Ogale S. Ann Oncol. 2018 Oct 1;29(10):2140. doi: 10.1093/annonc/mdy260. Ann Oncol. 2018. PMID: 30052727 Free PMC article. No abstract available.